Skip to main content

Table 3 Responder status for primary PRO measures from baseline to week 24 of the ATLAS study

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

  Placebo
(n = 107)
n (%)
Adalimumab 40 mg every other week
(n = 208)
n (%)
P valuea
SF-36 PCS, 0–50    
   Responder, ≥ 3-point reduction 41 (39.8) 138 (67.0) < 0.001
BASFI, 0–10    
   Responder, ≥ 21% reduction 38 (35.5) 142 (68.6) < 0.001
ASQOL, 0–18    
   Responder, ≥ 1.8-point reduction 46 (43.0) 135 (64.9) < 0.001
  1. aP-values based on chi-square test.
  2. ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASFI = Bath AS Functional Index; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.